Enhancing the circulating half-life of antibody-based fusion proteins
View Patent ↗Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.
1. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein the C-terminal non-Ig protein comprising an amino acid substitution introducing a hydrophobic or non-polar amino acid within 10 amino acids of the N-terminus of the C-terminal non-Ig protein, wherein said antibody-based fusion protein has a longer circulating half-life in vivo than a corresponding antibody-based fusion protein without said amino acid substitution.
2. The method of claim 1 , wherein said non-Ig protein is selected from the group consisting of a cytokine, a ligand-binding protein, and a protein toxin.
3. The method of claim 1 , wherein said non-Ig protein is interleukin-2.
4. The method of claim 1 , wherein the Ig chain comprises (i) a deletion of a charged amino acid within 10 amino acids of the C-terminus of the Ig chain, or (ii) an amino acid alteration introducing a hydrophobic or non-polar amino acid within 10 amino acids of the C-terminus of the Ig chain.
5. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein, the Ig chain comprising an IgG2, IgG3, IgG4, IgA, IgM, IgD, or IgE domain and an amino acid substitution introducing a hydrophobic or non-polar amino acid within 10 amino acids from the C-terminus of the Ig chain, wherein the antibody-based fusion protein has a longer circulating half-life in vivo than a corresponding antibody-based fusion protein without the amino acid substitution.
6. The method of claim 5 wherein the amino acid substitution increases the hydrophobicity of said antibody-based fusion protein.
7. The method of claim 5 wherein said substitution changes the C-terminal amino acid of the Ig chain.
8. The method of claim 5 , wherein the Ig chain comprises part of an Ig heavy chain.
9. The method of claim 8 , wherein said part of an Ig heavy chain has binding affinity for an immunoglobulin protection receptor.
10. The method of claim 5 comprising a linker between said Ig chain and said non-Ig protein.
11. The method of claim 5 , wherein said hydrophobic or non-polar amino acid is selected from the group consisting of Leu, Ala, Trp, and Gly.
12. The method of claim 11 , wherein said hydrophobic or non-polar amino acid is Ala.
13. The method of claim 5 wherein the constant domain comprises at least one of a CH1, CH2, or CH3 domain.
14. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein, the Ig chain comprising: at least one of a CH2 and CH3 domain; and an amino acid sequence that is non-natural within 10 amino acids from its C-terminus, the non-natural amino acid sequence comprising an amino acid substitution introducing a hydrophobic or non-polar amino acid, wherein the antibody-based fusion protein has a longer circulating half life in vivo than a corresponding antibody-based fusion protein without the amino acid substitution.
15. The method of claim 14 , wherein the Ig chain is an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgD, or IgE chain.
16. The method of claim 15 wherein the Ig chain comprises the CH2 domain of the IgG2 constant region and a C-terminal lysine is substituted with a nonpolar or hydrophobic amino acid.
17. The method of claim 16 , wherein the C-terminal lysine is substituted with an alanine.
18. The method of claim 16 , wherein the non-Ig protein is a cytokine.
19. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein, the Ig chain comprising an amino acid substitution within 10 amino acids from the C-terminus, the substitution replacing a charged amino acid with a hydrophobic or non-polar amino acid, wherein the antibody-based fusion protein has a longer circulating half life in vivo than a corresponding antibody-based fusion protein without the amino acid substitution.
20. The method of claim 19 , wherein the hydrophobic or non-polar amino acid is selected from the group consisting of Ala, Gly and Trp.